Definium Therapeutics to report Q3 2026 financials following momentum in late stage trials

Definium Therapeutics to report Q3 2026 financials following momentum in late stage trials
Definium to announce Q3 2026 results

Definium Therapeutics announced it will report its third quarter 2026 financial results and recent business updates in the near future. The company said this follows a year marked by significant progress, including three positive topline Phase 3 readouts.

Further details on the financial results and business developments are expected to be shared during the upcoming report.

Earlier this year, Definium Therapeutics provided updates on its Phase 3 studies of DT120 for major depressive disorder and anxiety at a leading neuropsychopharmacology event. Details of these clinical advancements were reported in a previous company announcement. The upcoming financial and business report will provide further information following these recent milestones.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.